Hot Investor Mandate 4: Korea Fund Opens US Office To Invest In Oncology, Opthalmology & Platform Technologies

29 Sep

An investment firm headquartered in Seoul, Korea, has established a US office in Boston to focus on US-based biotechnology companies. The firm invests from their third fund of $500 million. The firm is interested in opportunities at all stages of development and can allocate from $500 K up to $20 M in equity investments, acting as a lead or follow on.

The firm is currently focusing on the areas of immuno-oncology, gene therapy, ophthalmology, and platform technologies. Recent investments include companies targeting clinical stage small molecule therapeutics for oncology, peptide drugs for inflammatory diseases, and delivery methods and therapeutics in ophthamlology.

The story behind the company and management team is important to this firm. They look for a cohesive business plan and strategy, and are especially interested in opportunities with potential to expand into the Korean market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: